Navigation Links
Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients
Date:7/17/2011

PHILADELPHIA The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.

Based on these study results, lead researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now know that these women should get trastuzumab and potentially chemotherapy, even if cancer spreads to the brain."

"Women with HER2-positive breast cancer have a reasonable chance of living a long time with their disease, and they should be given aggressive therapy where appropriate," added Brufsky, professor of medicine and associate director of clinical investigation at the University of Pittsburgh Cancer Institute.

Ten to 16 percent of women with advanced breast cancer develop central nervous system metastases, the researchers wrote in their study, published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Brufsky and colleagues used data from the registHER study to evaluate the incidence, potential risk factors and outcomes for patients with HER2-positive breast cancer. They evaluated how patients with HER2-positive breast cancer develop brain metastases, and followed them to examine what happens thereafter.

Of the 1,023 women newly diagnosed with HER2-positive metastatic breast cancer, 377 had central nervous system metastases.

Patients with central nervous system metastases were younger, and more likely to have hormone receptornegative disease and higher disease burden compared with those whose cancer did not spread to the brain. In addition, for those patients without central nervous system metastases at initial diagnosis, cancer progressed to the brain about 13 months after diagnosis.

For those diagnosed with central nervous system metastases, treatment with trastuzumab, chemotherapy or surgery was each associated with a significant improve
'/>"/>

Contact: Tara Yates
Tara.Yates@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
2. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
3. York U researchers uncovering how ovarian cancer resists chemotherapy
4. Why chemotherapy causes more infertility in women than in men
5. A loose grip provides better chemotherapy
6. Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy
7. Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative
8. Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer
9. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
10. Identifying subsets of patients who will respond to subsequent lines of chemotherapy
11. New technology may prolong the life of implanted devices, from pacemakers to chemotherapy ports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... University,s work in protecting the lives and livelihoods of some ... prestigious national award. At the Times Higher Education awards ... the School of Planning, Architecture and Civil Engineering received the ... award recognises the team,s work in tackling the world,s worst ...
... the University of Leicester have identified for the first time ... of sugar in our blood following a meal. ... in helping to maintain correct blood sugar levels. The ... team led by Professor Andrew Tobin, Professor of Cell Biology, ...
... Universitaet Muenchen (TUM) have formed a strategic alliance for catalysis ... field of catalysis, a major aspect of this cooperation will ... to help meet the rising global demand for energy and ... this research work with up to two million euros a ...
Cached Biology News:Queen's life-saving research wins education 'Oscar' 2Up to 20 million euros for Munich Catalysis research cooperation 2Up to 20 million euros for Munich Catalysis research cooperation 3
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 /PRNewswire/ ... company advancing patient care in critical areas, announced the ... of common stock, and warrants to purchase up to ... offering price of $4.00 per share and $.01 per ... of $5.00, are exercisable immediately, and expire 5 years ...
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... December 23, 2014 According to Ross Selinger, ... Affiliate of ITRA Global, the national office market continues to ... This is evidenced by the third quarter’s surprising 3.9% ... Low energy costs have held inflation down and the ... is the housing market remaining soft. , This solid economic ...
(Date:12/24/2014)... San Diego, CA (PRWEB) December 23, 2014 ... Contest where their Twitter followers can submit their ... for themselves and their lab mates. , For those ... beloved lab mates, the Pipette.com Holiday in the Lab ... encourages Pipette.com Twitter followers to send pictures ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) today announced ... on Tuesday, November 6, 2007,following the close of the ... call and live audio webcast to discuss the,quarterly results ... p.m.,Eastern Time/2:00 p.m. Pacific Time. The live webcast ...
... Oct. 24 /PRNewswire-FirstCall/ - Atrium Innovations Inc. (TSX:,ATB) ... at 10 a.m. Eastern,time on November 8, 2007. ... 2007 third quarter results issued earlier the previous ... following numbers:,416-644-3418, 514-807-8791 or 800-591-7539 or via the ...
... IRVINE, Calif., Oct. 24 Cardiogenesis,Corporation (OTC: CGCP), ... third quarter ended September 30, 2007 prior to ... also said that President Richard,P. Lanigan and Senior ... will host an investor conference call that day ...
Cached Biology Technology:Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007 2Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8 2Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th 2
Artisan™ Wash Solution (x 50) Additional Information: EU regulatory status: CE US regulatory status: IVD ...
... Secondary Detection System is intended for use ... Antibody reagents, which contain rat and goat ... by light microscopy in paraffin-embedded tissues. The ... also be used with other rat or ...
... Lower operational costs. More efficient interfacing ... limited sample volumes. Industry demands for ... using microbore chromatography for routine applications. ... adequately satisfy the need to operate ...
... The Hepta adaptor for the PDS-1000 He ... be transformed than the standard system. It fits ... system, where it splits the helium shock wave ... gold or tungsten particles over this larger area, ...
Biology Products: